1. Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. Issue 7 (16th May 2018) Authors: Pierson, Sheila K.; Stonestrom, Aaron J.; Shilling, Dustin; Ruth, Jason; Nabel, Christopher S.; Singh, Amrit; Ren, Yue; Stone, Katie; Li, Hongzhe; van Rhee, Frits; Fajgenbaum, David C. Journal: American journal of hematology Issue: Volume 93:Issue 7(2018:Jul.) Page Start: 902 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. (11th September 2018) Authors: Morra, Deanna E.; Pierson, Sheila K.; Shilling, Dustin; Nemat, Sepideh; Appiani, Carlos; Guilfoyle, Mary; Tendler, Craig; van Rhee, Frits; Fajgenbaum, David C. Journal: British journal of haematology Issue: Volume 184:Number 2(2019) Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. Issue 1 (13th March 2019) Authors: Zuccato, Mary; Shilling, Dustin; Fajgenbaum, David C. Editors: MacKenzie, Alex; Groft, Stephen; Justice, Monica; van Karnebeek, Clara Journal: Emerging topics in life sciences Issue: Volume 3:Issue 1(2019) Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗